Capmatinib Hydrochloride Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as NOVARTIS PHARM. It is marketed under 1 brand name, including TABRECTA. Available in 2 different strengths, such as EQ 150MG BASE, EQ 200MG BASE, and administered through 1 route including TABLET;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"130741","ingredient":"CAPMATINIB HYDROCHLORIDE","trade_name":"TABRECTA","family_id":"f0dce381ef974dedb579","publication_number":"US12084449B2","cleaned_patent_number":"12084449","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-11-19","publication_date":"2024-09-10","legal_status":"Granted"} US12084449B2 10 Sep, 2024 Granted 19 Nov, 2027
{"application_id":"100134","ingredient":"CAPMATINIB HYDROCHLORIDE","trade_name":"TABRECTA","family_id":"f0dce381ef974dedb579","publication_number":"US8461330B2","cleaned_patent_number":"8461330","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-11-19","publication_date":"2013-06-11","legal_status":"Granted"} US8461330B2 Molecular Formulation 11 Jun, 2013 Granted 19 Nov, 2027
{"application_id":"100042","ingredient":"CAPMATINIB HYDROCHLORIDE","trade_name":"TABRECTA","family_id":"8432ccdc4c2c4b98bc83","publication_number":"US8901123B2","cleaned_patent_number":"8901123","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-05-20","publication_date":"2014-12-02","legal_status":"Patented case"} US8901123B2 02 Dec, 2014 Patented case 20 May, 2029
{"application_id":"100084","ingredient":"CAPMATINIB HYDROCHLORIDE","trade_name":"TABRECTA","family_id":"8432ccdc4c2c4b98bc83","publication_number":"US8420645B2","cleaned_patent_number":"8420645","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-06-05","publication_date":"2013-04-16","legal_status":"Granted"} US8420645B2 Molecular Formulation 16 Apr, 2013 Granted 05 Jun, 2031
{"application_id":"100199","ingredient":"CAPMATINIB HYDROCHLORIDE","trade_name":"TABRECTA","family_id":"f0dce381ef974dedb579","publication_number":"US7767675B2","cleaned_patent_number":"7767675","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-11-19","publication_date":"2010-08-03","legal_status":"Granted"} US7767675B2 Molecular Formulation 03 Aug, 2010 Granted 19 Nov, 2032
{"application_id":"100092","ingredient":"CAPMATINIB HYDROCHLORIDE","trade_name":"TABRECTA","family_id":"ade31ccb80834670972f","publication_number":"US10596178B2","cleaned_patent_number":"10596178","drug_product_flag":"Y","drug_substance_flag":"-, Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-07-22","publication_date":"2020-03-24","legal_status":"Granted"} US10596178B2 Formulation 24 Mar, 2020 Granted 22 Jul, 2035
{"application_id":"139435","ingredient":"CAPMATINIB HYDROCHLORIDE","trade_name":"TABRECTA","family_id":"","publication_number":"US12208101B2","cleaned_patent_number":"12208101","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-07-22","publication_date":"2025-01-28","legal_status":"Granted"} US12208101B2 Formulation 28 Jan, 2025 Granted 22 Jul, 2035

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Capmatinib Hydrochloride

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.